Multicentric Phase II Study of Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer, With :- Induction Chemotherapy by Cisplatin - Docetaxel- Concomitant Chemo-radiotherapy by Weekly Cisplatin - Docetaxel- Consolidation Chemotherapy by Docetaxel
Inclusion Criteria
Inclusion criteria:
Histologically or cytologically confirmed newly diagnosed, untreated, unresectable stage
IIIA or stage IIIB non-small cell lung cancer Not scheduled for curative cancer surgery No
pleural effusion At least 1 bidimensionally or unidimensionally measurable lesion Age 18
years et 70 years; Performance Status < 2 Loss of weight < 10 % in past 6 months life
expectancy 12 weeks; Bilirubin normal ASAT (SGOT) et ALAT (SGPT) 1,5 times upper limit of
normal; Alcalin phosphatases 5 times upper limit of normal; Créatinin 1,5 x times upper
limit of normal; Absolute neutrophil count greater than 2.109/l; Platelet count greater
than 100.109/l; Hémoglobin ³ 10 g/ dl; Respiratory function : FEV1>50% write Consent
Exclusion criteria:
Pregnant or nursing; Fertile patients who don't used effective contraception; No other
malignancy within past 5 years except inactive carcinoma in situ of the cervix or
nonmelanoma skin cancer ; Neuropathy grade NCI-CTC 2; Past thoracic radiotherapy; Past
chemotherapy, immunotherapy or biologic therapy for non small cell lung cancer ;
Respiratory deficiency FEV1 < 45% ; Hypersensibility to docetaxel or cisplatin; At least 4
weeks since other concurrent investigational agents;